Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
Abstract
:1. Introduction
2. Prevention and Treatment of OHP-Related Peripheral Neurotoxicity
2.1. Pharmacological Studies
2.1.1. Riluzole
2.1.2. L-Carnosine
2.1.3. Lidocaine
2.1.4. Venlafaxine
2.1.5. Calmangafodipir
2.1.6. Pregabalin
2.1.7. Duloxetine
2.1.8. Lorcaserin
2.1.9. TRK-750
2.2. Non-Pharmacological Studies
2.2.1. Repetitive Transcranial Magnetic Stimulation
2.2.2. Strength and Balance Training Program
2.2.3. Diet
2.2.4. Henna Application
3. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Cavaletti, G.; Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity. Curr. Opin. Neurol. 2015, 28, 500–507. [Google Scholar] [CrossRef] [PubMed]
- Grisold, W.; Cavaletti, G.; Windebank, A.J. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro Oncol. 2012, 14 (Suppl. 4), 45–54. [Google Scholar] [CrossRef] [Green Version]
- Cavaletti, G.; Tredici, G.; Petruccioli, M.G.; Dondè, E.; Tredici, P.; Marmiroli, P.; Minoia, C.; Ronchi, A.; Bayssas, M.; Etienne, G.G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer 2001, 37, 2457–2463. [Google Scholar] [CrossRef]
- Marmiroli, P.; Riva, B.; Pozzi, E.; Ballarini, E.; Lim, D.; Chiorazzi, A.; Meregalli, C.; Distasi, C.; Renn, C.L.; Semperboni, S.; et al. Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. PLoS ONE 2017, 12, e0186250. [Google Scholar] [CrossRef] [PubMed]
- Avan, A.; Postma, T.J.; Ceresa, C.; Cavaletti, G.; Giovannetti, E.; Peters, G.J. Platinum-induced neurotoxicity and preventive strategies: Past; Present; and Future. Oncologist 2015, 20, 411–432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Argyriou, A.A.; Velasco, R.; Briani, C.; Cavaletti, G.; Bruna, J.; Alberti, P.; Cacciavillani, M.; Lonardi, S.; Santos, C.; Cortinovis, D.; et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients. Ann. Oncol. 2012, 23, 3116–3122. [Google Scholar] [CrossRef] [PubMed]
- Argyriou, A.A.; Cavaletti, G.; Briani, C.; Velasco, R.; Bruna, J.; Campagnolo, M.; Alberti, P.; Bergamo, F.; Cortinovis, D.; Cazzaniga, M.; et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. Cancer 2013, 119, 438–444. [Google Scholar] [CrossRef] [Green Version]
- Grisold, W.; Grisold, A.; Löscher, W.N. Neuromuscular complications in cancer. J. Neurol. Sci. 2016, 367, 184–202. [Google Scholar] [CrossRef]
- Kawashiri, T.; Egashira, N.; Kurobe, K.; Tsutsumi, K.; Yamashita, Y.; Ushio, S.; Yamashita, Y.; Ushio, S.; Yano, T.; Oishi, R. L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol. Pain 2012, 8, 7. [Google Scholar] [CrossRef] [Green Version]
- Park, S.B.; Lin, C.S.; Kiernan, M.C. Nerve excitability assessment in chemotherapy-induced neurotoxicity. J. Vis. Exp. 2012, 26, 3439. [Google Scholar] [CrossRef] [Green Version]
- Krishnan, A.V.; Goldstein, D.; Friedlander, M.; Kiernan, M.C. Oxaliplatin and axonal Na+ channel function in vivo. Clin. Cancer Res. 2006, 12, 4481–4484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gamelin, E.; Gamelin, L.; Bossi, L.; Quasthoff, S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin. Oncol. 2002, 29 (Suppl. 15), 21–33. [Google Scholar] [CrossRef] [PubMed]
- Adelsberger, H.; Quasthoff, S.; Grosskreutz, J.; Lepier, A.; Eckel, F.; Lersch, C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 2000, 406, 25–32. [Google Scholar] [CrossRef]
- Benoit, E.; Brienza, S.; Dubois, J.M. Oxaliplatin; an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen. Physiol. Biophys. 2006, 25, 263–276. [Google Scholar] [PubMed]
- Alberti, P.; Canta, A.; Chiorazzi, A.; Fumagalli, G.; Meregalli, C.; Monza, L.; Pozzi, E.; Ballarini, E.; Rodriguez-Menendez, V.; Oggioni, N.; et al. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity. Neuropharmacology 2020, 164, 107905. [Google Scholar] [CrossRef] [PubMed]
- Bennedsgaard, K.; Ventzel, L.; Grafe, P.; Tigerholm, J.; Themistocleous, A.C.; Bennett, D.L.; Tankisi, H.; Finnerup, N.B. Cold aggravates abnormal excitability of motor axons in oxaliplatin-treated patients. Muscle Nerve 2020. [Google Scholar] [CrossRef] [PubMed]
- Heide, R.; Bostock, H.; Ventzel, L.; Grafe, P.; Bergmans, J.; Fuglsang-Frederiksen, A.; Finnerup, N.B.; Tankisi, H. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation. Clin. Neurophysiol. 2018, 129, 694–706. [Google Scholar] [CrossRef]
- Riva, B.; Dionisi, M.; Potenzieri, A.; Chiorazzi, A.; Cordero-Sanchez, C.; Rigolio, R.; Carozzi, V.A.; Lim, D.; Cavaletti, G.; Marmiroli, P.; et al. Oxaliplatin induces pH acidification in dorsal root ganglia neurons. Sci. Rep. 2018, 8, 15084. [Google Scholar] [CrossRef] [Green Version]
- Potenzieri, A.; Riva, B.; Rigolio, R.; Chiorazzi, A.; Pozzi, E.; Ballarini, E.; Cavaletti, G.; Genazzani, A.A. Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors. Pain 2020, 161, 405–415. [Google Scholar] [CrossRef]
- Cavaletti, G.; Tredici, G.; Marmiroli, P.; Petruccioli, M.G.; Barajon, I.; Fabbrica, D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992, 84, 364–371. [Google Scholar] [CrossRef]
- Renn, C.L.; Carozzi, V.A.; Rhee, P.; Gallop, D.; Dorsey, S.G.; Cavaletti, G. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol. Pain 2011, 7, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Di Cesare Mannelli, L.; Pacini, A.; Micheli, L.; Tani, A.; Zanardelli, M.; Ghelardini, C. Glial role in oxaliplatin-induced neuropathic pain. Exp. Neurol. 2014, 261, 22–33. [Google Scholar] [CrossRef] [PubMed]
- Podratz, J.L.; Knight, A.M.; Ta, L.E.; Staff, N.P.; Gass, J.M.; Genelin, K.; Schlattau, A.; Lathroum, L.; Windebank, A.J. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol. Dis. 2011, 41, 661–668. [Google Scholar] [CrossRef] [Green Version]
- Xiao, W.H.; Bennett, G.J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012, 153, 704–709. [Google Scholar] [CrossRef] [Green Version]
- Zheng, H.; Xiao, W.H.; Bennett, G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neurol. 2011, 232, 154–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Makker, P.G.; Duffy, S.S.; Lees, J.G.; Perera, C.J.; Tonkin, R.S.; Butovsky, O.; Park, S.B.; Goldstein, D.; Moalem-Taylor, G. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS ONE 2017, 12, e0170814. [Google Scholar] [CrossRef] [PubMed]
- Starobova, H.; Vetter, I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front. Mol. Neurosci. 2017, 10, 174. [Google Scholar] [CrossRef]
- Sprowl, J.A.; Ong, S.S.; Gibson, A.A.; Hu, S.; Du, G.; Lin, W.; Li, L.; Bharill, B.; Ness, R.A.; Stecula, A.; et al. A phosphotyrosine switch regulates organic cation transporters. Nat. Commun. 2016, 7, 10880. [Google Scholar] [CrossRef]
- Harrach, S.; Ciarimboli, G. Role of transporters in the distribution of platinum-based drugs. Front. Pharmacol. 2015, 6, 85. [Google Scholar] [CrossRef] [Green Version]
- Argyriou, A.A.; Bruna, J.; Genazzani, A.A.; Cavaletti, G. Chemotherapy-induced peripheral neurotoxicity: Management informed by pharmacogenetics. Nat. Rev. Neurol. 2017, 13, 492–504. [Google Scholar] [CrossRef]
- Cavaletti, G.; Alberti, P.; Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011, 12, 1151–1161. [Google Scholar] [CrossRef]
- Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Lavoie Smith, E.M.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lavino, A.; Lustberg, M.B.; et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014, 32, 1941–1967. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Albers, J.W.; Chaudhry, V.; Cavaletti, G.; Donehower, R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. 2014, 3, CD005228. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, S.; Ushio, S.; Egashira, N.; Kawashiri, T.; Mitsuyasu, S.; Higuchi, H.; Ozawa, N.; Masuguchi, K.; Ono, Y.; Masuda, S. Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: A possibility for riluzole as a prophylactic drug. Sci. Rep. 2017, 7, 9661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poupon, L.; Lamoine, S.; Pereira, V.; Barriere, D.A.; Lolignier, S.; Giraudet, F.; Aissouni, Y.; Meleine, M.; Prival, L.; Richard, D.; et al. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology 2018, 140, 43–61. [Google Scholar] [CrossRef] [Green Version]
- Descoeur, J.; Pereira, V.; Pizzoccaro, A.; Francois, A.; Ling, B.; Maffre, V.; Couette, B.; Busserolles, J.; Courteix, C.; Noel, J.; et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 2011, 3, 266–278. [Google Scholar] [CrossRef]
- Noël, J.; Zimmermann, K.; Busserolles, J.; Deval, E.; Alloui, A.; Diochot, S.; Guy, N.; Borsotto, M.; Reeh, P.; Eschalier, A.; et al. The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. EMBO J. 2009, 28, 1308–1318. [Google Scholar] [CrossRef] [Green Version]
- Nativi, C.; Gualdani, R.; Dragoni, E.; Di Cesare Mannelli, L.; Sostegni, S.; Norcini, M.; Gabrielli, G.; la Marca, G.; Richichi, B.; Francesconi, O.; et al. A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci. Rep. 2013, 3, 2005. [Google Scholar] [CrossRef] [Green Version]
- Van den Heuvel, S.A.S.; van der Wal, S.E.I.; Smedes, L.A.; Radema, S.A.; van Alfen, N.; Vissers, K.C.P.; Steegers, M.A.H. Intravenous lidocaine: Old-school drug; new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res. Manag. 2017, 2017, 8053474. [Google Scholar]
- Zimmerman, C.; Atherton, P.J.; Pachman, D.; Seisler, D.; Wagner-Johnston, N.; Dakhil, S.; Lafky, J.M.; Qin, R.; Grothey, A.; Loprinzi, C.L. MC11C4: A pilot randomized; placebo-controlled; double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support. Care Cancer 2016, 24, 1071–1078. [Google Scholar] [CrossRef] [Green Version]
- Karlsson, J.O.; Ignarro, L.J.; Lundström, I.; Jynge, P.; Almén, T. Calmangafodipir Ca4Mn(DPDP)5, mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov. Today 2015, 20, 411–421. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karlsson, J.O.; Kurz, T.; Flechsig, S.; Näsström, J.; Andersson, R.G. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl. Oncol. 2012, 5, 492–502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Glimelius, B.; Manojlovic, N.; Pfeiffer, P.; Mosidze, B.; Kurteva, G.; Karlberg, M.; Mahalingam, D.; Buhl Jensen, P.; Kowalski, J.; Bengtson, M.; et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx). Acta Oncol. 2018, 57, 393–402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Andrade, D.C.; Jacobsen Teixeira, M.; Galhardoni, R.; Ferreira, K.S.L.; Braz Mileno, P.; Scisci, N.; Zandonai, A.; Teixeira, W.J.; Saragiotto, D.F.; Silva, V.; et al. Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: A randomized; double-blind trial. Oncologist 2017, 22, 1154-e105. [Google Scholar] [CrossRef] [Green Version]
- Smith, E.M.; Pang, H.; Ye, C.; Cirrincione, C.; Fleishman, S.; Paskett, E.D.; Ahles, T.; Bressler, L.R.; Le-Lindqwister, N.; Fadul, C.E.; et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): A secondary analysis of randomised controlled trial—CALGB/alliance 170601. Eur. J. Cancer Care 2017, 26. [Google Scholar] [CrossRef] [Green Version]
- Higgins, G.A.; Fletcher, P.J.; Shanahan, W.R. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol. Ther. 2020, 205, 107417. [Google Scholar] [CrossRef]
- Yang, S.; Chang, M.C. Effect of repetitive transcranial magnetic stimulation on pain management: A systematic narrative review. Front. Neurol. 2020, 11, 114. [Google Scholar] [CrossRef] [Green Version]
- Derksen, T.M.; Bours, M.J.; Mols, F.; Weijenberg, M.P. Lifestyle-related factors in the self-management of chemotherapy-induced peripheral neuropathy in colorectal cancer: A systematic review. Evid. Based Complement. Alternat. Med. 2017, 2017, 7916031. [Google Scholar] [CrossRef] [Green Version]
- Soliman, A.M.; Teoh, S.L.; Ghafar, N.A.; Das, S. Molecular Concept of Diabetic Wound Healing: Effective role of herbal remedies. Mini. Rev. Med. Chem. 2019, 19, 381–394. [Google Scholar] [CrossRef]
- Gewandter, J.S.; Gibbons, C.H.; Campagnolo, M.; Lee, J.; Chaudari, J.; Ward, N.; Burke, L.; Cavaletti, G.; Herrmann, D.N.; McArthur, J.C.; et al. Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review. Neurology 2019, 93, 346–360. [Google Scholar] [CrossRef]
- Alberti, P.; Rossi, E.; Cornblath, D.R.; Merkies, I.S.J.; Postma, T.J.; Frigeni, B.; Bruna, J.; Velasco, R.; Argyriou, A.A.; Kalofonos, H.P.; et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin. Ann. Oncol. 2014, 25, 257–264. [Google Scholar] [CrossRef] [PubMed]
- Griffith, K.A.; Dorsey, S.G.; Renn, C.L.; Zhu, S.; Johantgen, M.E.; Cornblath, D.R.; Argyriou, A.A.; Cavaletti, G.; Merkies, I.S.J.; Alberti, P.; et al. Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: Secondary analysis of data from the CI-PeriNomS study. J. Peripher. Nerv. Sys. 2014, 19, 127–135. [Google Scholar] [CrossRef] [PubMed]
- Cavaletti, G.; Cornblath, D.R.; Merkies, I.S.J.; Postma, T.J.; Rossi, E.; Frigeni, B.; Alberti, P.; Bruna, J.; Velasco, R.; Argyriou, A.A.; et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Ann. Oncol. 2013, 24, 454–462. [Google Scholar] [CrossRef] [PubMed]
- Meregalli, C.; Fumagalli, G.; Alberti, P.; Canta, A.; Carozzi, V.A.; Chiorazzi, A.; Monza, L.; Pozzi, E.; Sandelius, A.; Blennow, K.; et al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp. Neurol. 2018, 307, 129–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meregalli, C.; Fumagalli, G.; Alberti, P.; Canta, A.; Chiorazzi, A.; Monza, L.; Pozzi, E.; Carozzi, V.A.; Blennow, K.; Zetterberg, H.; et al. Neurofilament light chain: A specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Arch. Toxicol. 2020. [Google Scholar] [CrossRef]
- Tsubota, M.; Fukuda, R.; Hayashi, Y.; Miyazaki, T.; Ueda, S.; Yamashita, R.; Koike, N.; Sekiguchi, F.; Wake, H.; Wakatsuki, S.; et al. Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: Negative impact of anticoagulants. J. Neuroinflammation 2019, 16, 199. [Google Scholar] [CrossRef]
- Miguel, C.A.; Raggio, M.C.; Villar, M.J.; Gonzalez, S.L.; Coronel, M.F. Anti-allodynic and anti-inflammatory effects of 17α-hydroxyprogesterone caproate in oxaliplatin-induced peripheral neuropathy. J. Peripher. Nerv. Syst. 2019, 4, 100–110. [Google Scholar] [CrossRef] [Green Version]
- Yamamoto, S.; Yamashita, T.; Ito, M.; Caaveiro, J.M.M.; Egashira, N.; Tozaki-Saitoh, H.; Tsuda, M. New pharmacological effect of fulvestrant to prevent oxaliplatin-induced neurodegeneration and mechanical allodynia in rats. Int. J. Cancer 2019, 145, 2107–2113. [Google Scholar] [CrossRef]
- Kawashiri, T.; Miyagi, A.; Shimizu, S.; Shigematsu, N.; Kobayashi, D.; Shimazoe, T. Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro. J. Pharmacol. Sci. 2018, 137, 202–211. [Google Scholar] [CrossRef]
- Cerles, O.; Gonçalves, T.C.; Chouzenoux, S.; Benoit, E.; Schmitt, A.; Bennett Saidu, N.E.; Kavian, N.; Chéreau, C.; Gobeaux, C.; Weill, B.; et al. Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth. Acta Neuropathol. Commun. 2019, 7, 9. [Google Scholar] [CrossRef]
- Ren, X.; Boriero, D.; Chaiswing, L.; Bondada, S.; St Clai, D.K.; Butterfield, D.A. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”); A condition that significantly impairs the quality of life of many cancer survivors. Biochim. Biophys Acta Mol. Basis Dis. 2019, 1865, 1088–1097. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, L.D.; Ehrlich, B.E. Cellular mechanisms and treatments for chemobrain: Insight from aging and neurodegenerative diseases. EMBO Mol. Med. 2020. [Google Scholar] [CrossRef] [PubMed]
- Cerulla Torrente, N.; Navarro Pastor, J.B.; de la Osa Chaparro, N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. J. Cancer Surviv. 2020. [Google Scholar] [CrossRef] [PubMed]
- Quintão, N.L.M.; Santin, J.R.; Stoeberl, L.C.; Corrêa, T.P.; Melato, J.; Costa, R. Pharmacological treatment of chemotherapy-induced neuropathic pain: PPARγ agonists as a promising tool. Front. Neurosci. 2019, 13, 907. [Google Scholar] [CrossRef]
- Iveson, T.J.; Kerr, R.S.; Saunders, M.P.; Cassidy, J.; Hollander, N.H.; Tabernero, J.; Haydon, A.; Glimelius, B.; Harkin, A.; Allan, K.; et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): An international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018, 19, 562–578. [Google Scholar] [CrossRef] [Green Version]
# | Title of the Trial | Number of Patients | Last Updated | Allocation | Intervention Model | Masking | Status |
---|---|---|---|---|---|---|---|
1 | Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy | 210 | Oct 9, 2019 | randomized | parallel assignment | quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) | Not yet recruiting |
2 | L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients | 65 | Apr 24, 2017 | randomized | parallel assignment | none | Completed |
3 | Lidocaine for Oxaliplatin-induced Neuropathy | 38 | Jan 22, 2020 | randomized | parallel assignment | quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) | Recruiting |
4 | Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy | 50 | Sep 26, 2019 | randomized | parallel assignment | double (Participant, Investigator) | Completed |
5 | Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) | 420 | Mar 27, 2020 | randomized | parallel assignment | triple (Participant, Care Provider, Investigator) | Recruiting |
6 | Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer | 301 | Feb 20, 2020 | randomized | parallel assignment | triple (Participant, Care Provider, Investigator) | Active, not recruiting |
7 | Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy | 200 | May 9, 2017 | randomized | parallel assignment | quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) | Completed |
8 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II–III Colorectal Cancer | 327 | Feb 20, 2020 | randomized | Sequential Assignment | double (Participant, Investigator) | Not yet recruiting |
9 | Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | 50 | Apr 4, 2019 | randomized | parallel assignment | coded bottles | Not yet recruiting |
10 | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I–IV Gastrointestinal or Breast Cancer | 30 | Dec 19, 2019 | Single Group Assignment | none | Not yet recruiting | |
11 | A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study) | 240 | Feb 25, 2020 | randomized | Crossover Assignment | triple (Participant, Care Provider, Investigator) | Not yet recruiting |
# | Title of Trial | Number of Patients | Last Updated | Allocation | Intervention Model | Masking | Status |
---|---|---|---|---|---|---|---|
1 | Use of Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Oxaliplatin-Induced Peripheral Neuropathy | 60 | Sep 27, 2019 | randomized | parallel assignment | Double (Participant, Outcomes Assessor) | Not yet recruiting |
3 | Rtms in Improving Neuropathy in Patients With Stage I–IV Cancer Who Have Received Oxaliplatin Chemotherapy | 60 | Mar 6, 2020 | randomized | parallel assignment | Double (Participant, Outcomes Assessor) | Recruiting |
2 | Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy | 4 | Dec 29, 2016 | single group | none | Completed | |
4 | Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet | 80 | Jul 11, 2017 | randomized | parallel assignment | single (Participant) | Completed |
11 | The Preliminary Effects of Henna on CIPN | 60 | Dec 17, 2019 | randomized | parallel assignment | single (Outcome Assessor) | Completed |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cavaletti, G.; Marmiroli, P. Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers 2020, 12, 1370. https://doi.org/10.3390/cancers12061370
Cavaletti G, Marmiroli P. Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers. 2020; 12(6):1370. https://doi.org/10.3390/cancers12061370
Chicago/Turabian StyleCavaletti, Guido, and Paola Marmiroli. 2020. "Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy" Cancers 12, no. 6: 1370. https://doi.org/10.3390/cancers12061370